Appointed
Vicki Goodman
Chief Medical Officer
RECURSION PHARMACEUTICALS, INC.
Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026
leadership
confidence high
sentiment neutral
materiality 0.55
Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out
RECURSION PHARMACEUTICALS, INC.
- Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.
- Outgoing CMO Dr. Mauro will serve as advisor until May 29, 2026, after three years at Recursion.
- CEO Najat Khan highlights Goodman's late-stage clinical development experience for advancing pipeline.
- Company reiterates key clinical and regulatory milestones consistent with prior expectations.
item 5.02item 7.01item 9.01
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Role change
David Mauro
Chief Medical Officer
RECURSION PHARMACEUTICALS, INC.
as David Mauro, M.D., Ph.D. transitions out of the role.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.